DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Cvm-1118, Foslinanib [inn], Foslinanib [usan], Trx 818, Trx-818, 2x2dnm7ngx

Molecular Formula

C₁₆H₁₃FNO₆P

Molecular Weight

365.25 g/mol

InChI Key

ZDWFMAHQGDEALT-UHFFFAOYSA-N

FDA UNII

2X2DNM7NGX

Foslinanib is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.

1 2D Structure

Foslinanib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[2-(3-fluorophenyl)-6-methoxy-4-oxo-1H-quinolin-5-yl] dihydrogen phosphate

2.1.2 InChI

InChI=1S/C16H13FNO6P/c1-23-14-6-5-11-15(16(14)24-25(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9/h2-8H,1H3,(H,18,19)(H2,20,21,22)

2.1.3 InChI Key

ZDWFMAHQGDEALT-UHFFFAOYSA-N

2.1.4 Canonical SMILES

COC1=C(C2=C(C=C1)NC(=CC2=O)C3=CC(=CC=C3)F)OP(=O)(O)O

2.2 Other Identifiers

2.2.1 UNII

2X2DNM7NGX

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Phosphate

2. Fmod Phosphate

3. Sodium 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Phosphate

2.3.2 Depositor-Supplied Synonyms

1. Cvm-1118

2. Foslinanib [inn]

3. Foslinanib [usan]

4. Trx 818

5. Trx-818

6. 2x2dnm7ngx

7. Trx-818 Free Acid

8. Cvm-1118 Free Acid

9. 1256037-60-1

10. 4(1h)-quinolinone, 2-(3-fluorophenyl)-6-methoxy-5-(phosphonooxy)-

11. 2-(3-fluorophenyl)-4-hydroxy-6-methoxyquinolin-5-yl Dihydrogen Phosphate

12. 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Dihydrogen Phosphate

13. 2054938-73-5

14. Foslinanib (usan/inn)

15. Foslinanib [usan:inn]

16. Unii-2x2dnm7ngx

17. Foslinanib [who-dd]

18. Schembl339272

19. Chembl1615993

20. Gtpl11621

21. Who 10721

22. D11639

23. 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Phosphate

24. [2-(3-fluorophenyl)-6-methoxy-4-oxo-1h-quinolin-5-yl] Dihydrogen Phosphate

2.4 Create Date

2011-01-24

3 Chemical and Physical Properties

Molecular Formula	C₁₆H₁₃FNO₆P
Molecular Weight	365.25 g/mol
XLogP3	1.6
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	4
Exact Mass	365.04645229 g/mol
Monoisotopic Mass	365.04645229 g/mol
Topological Polar Surface Area	105 Å²
Heavy Atom Count	25
Formal Charge	0
Complexity	593
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1